Wood W J, Rawlings M, Evans H, Lim C N
Department of Surgery, University of Texas System Cancer Center, M.D. Anderson Hospital and Tumor Institute, Houston.
Am J Surg. 1988 May;155(5):663-6. doi: 10.1016/s0002-9610(88)80139-9.
The characteristics and clinical courses of 15 patients with fibrolamellar carcinoma have been compared to 62 patients with hepatocellular carcinoma treated over the same time period. Marked differences were found in patient, tumor, and treatment characteristics. Survival rates in these two groups of patients have been compared by univariate analysis of the subsets of those patient, tumor, and treatment characteristics. The longer survival of the group of patients with fibrolamellar carcinoma could not be accounted for by the prevalence or absence of any of these characteristics. Comparison of subsets of patients with documented noncirrhotic livers or those having complete resection of their tumors revealed a significantly prolonged survival in patients with the fibrolamellar variant. The 5 year survival rate of the patients with fibrolamellar carcinoma who had complete tumor resection was 45 percent, with a median survival time of 50 months. The 5 year survival of patients with hepatocellular carcinoma who had complete tumor resection was 0 percent, with a median survival time of 22 months.
对15例纤维板层癌患者的特征和临床病程与同期接受治疗的62例肝细胞癌患者进行了比较。在患者、肿瘤和治疗特征方面发现了显著差异。通过对这些患者、肿瘤和治疗特征子集的单因素分析,比较了这两组患者的生存率。纤维板层癌患者组较长的生存期无法用这些特征中的任何一个的存在或不存在来解释。对有记录的非肝硬化肝脏患者或肿瘤完全切除患者的子集进行比较,发现纤维板层变体患者的生存期显著延长。肿瘤完全切除的纤维板层癌患者的5年生存率为45%,中位生存期为50个月。肿瘤完全切除的肝细胞癌患者的5年生存率为0%,中位生存期为22个月。